HIV/AIDSSymptoms, Doctors, Treatments, Advances & More
Learn About HIV/AIDS
Human immunodeficiency virus (HIV) is the virus that causes acquired immunodeficiency syndrome (AIDS). When a person becomes infected with HIV, the virus attacks and weakens the immune system. As the immune system weakens, the person is at risk for getting life-threatening infections and cancers. When that happens, the illness is called AIDS. Once a person has the virus, it stays inside the body for life.
HIV infection; Infection - HIV; Human immunodeficiency virus; Acquired immune deficiency syndrome: HIV-1
The virus is spread (transmitted) person-to-person through certain body fluids:
- Blood
- Semen and preseminal fluid
- Rectal fluids
- Vaginal fluids
- Breast milk
HIV can be spread if these fluids come in contact with:
- Mucous membranes (inside of the mouth, penis, vagina, rectum)
- Damaged tissue (tissue that has been cut or scraped)
- The blood stream by injection
HIV cannot be spread through sweat, saliva, or urine.
In the United States, HIV is mainly spread:
- Through vaginal or anal sex without using a condom with someone who has HIV who is not taking medicines to prevent or treat HIV
- Through needle sharing or other equipment used to inject illicit drugs with someone who has HIV
Less often, HIV is spread:
- From mother to child. A pregnant woman can spread the virus to her unborn baby (fetus) through their shared blood circulation, or a nursing mother can pass it to her baby through her breast milk. Testing and treatment of HIV-positive mothers has helped lower the number of babies getting HIV.
- Through needle sticks or other sharp objects that are contaminated with HIV (mainly health care workers).
The virus is not spread by:
- Casual contact, such as hugging or closed-mouth kissing
- Mosquitoes or pets
- Participating in sports
- Touching items that were touched by a person infected with the virus
- Eating food handled by a person with HIV
- Intimate contact with an HIV-positive person with a stably undetectable viral load
HIV and blood or organ donation:
- HIV is not spread to a person who donates blood or organs. People who donate organs are never in direct contact with the people who receive them. Likewise, a person who donates blood is never in contact with the person receiving it. In all of these procedures, sterile needles and instruments are used.
- Blood banks and organ donor programs thoroughly check (screen) donors, blood, and tissues. It is very unlikely to get HIV from blood transfusions, blood products, or organ or tissue transplants.
Risk factors for getting HIV include:
- Having unprotected anal or vaginal sex. Receptive anal sex is the riskiest. Having multiple partners also increases the risk. Using a new condom correctly every time you have sex greatly helps lower this risk.
- Using illicit drugs and sharing needles or syringes used to inject them.
- Having a sexual partner with HIV who is not taking HIV medicines or who has a detectable viral load.
- Having a sexually-transmitted disease (STD).
Symptoms related to acute HIV infection (when a person is first infected) can be similar to the flu or other viral illnesses. They include:
- Fever and muscle pains
- Headache
- Sore throat
- Night sweats
- Mouth sores, including yeast infection (thrush)
- Swollen lymph glands
- Diarrhea
Many people have no symptoms when they are first infected with HIV.
Acute HIV infection (Stage 1) progresses over a few weeks to months to become chronic or asymptomatic HIV infection (Stage 2) (no symptoms). This stage can last 10 years or longer (not common). During this period, the person might have no reason to suspect they have HIV, but they can spread the virus to others.
If they are not treated, almost all people infected with HIV will develop AIDS (Stage 3). Some people develop AIDS within a few years of infection. Others remain completely healthy after 10 or even 20 years (called long-term nonprogressors).
People with AIDS have had their immune system seriously damaged by HIV. They are at very high risk of getting infections that are uncommon in people with a healthy immune system. These infections are called opportunistic infections and can affect any part of the body. These can be caused by:
- Bacteria
- Viruses
- Fungi
- Protozoa
People with AIDS are also at higher risk for certain cancers, especially lymphomas and a skin cancer called Kaposi sarcoma.
Symptoms depend on the particular infection and which part of the body is infected.
Lung infections are common in people with AIDS and often cause cough, fever, and shortness of breath.
Intestinal infections are also common and can cause:
- Diarrhea
- Abdominal pain
- Vomiting
- Swallowing problems
Other common symptoms in people with HIV infection and AIDS include:
- Weight loss
- Fever
- Sweats
- Rashes
- Swollen lymph glands
HIV/AIDS is treated with medicines that stop the virus from multiplying. This treatment is called antiretroviral therapy (ART).
In the past, people with HIV infection would start antiretroviral treatment after their CD4 count dropped or they developed HIV complications. Today, HIV treatment is recommended for all people with HIV infection, even if their CD4 count is still normal.
There are two types or treatment:
- Pills are given to people who are just starting treatment.
- Shots may be given to people who have an undetectable viral load or who have been virally suppressed for at least 3 months. Depending on the exact medicine used, shots may be given every month or every other month.
Regular blood tests are needed to make sure the virus level in the blood (viral load) is kept low or suppressed. The goal of treatment is to lower the HIV virus load in the blood to a level that is so low that the test can't detect it. This is called an undetectable viral load.
If the CD4 count already dropped before treatment was started, it will usually slowly go up. HIV complications often disappear as the immune system recovers.
Brigham And Women's Hospital, Division Of Infectious Diseases
Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is now the Harriet Ryan Albee Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He has served on numerous NIH committees, including as a member of the NIH Office of AIDS Research Advisory Council. He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors. He has been a member of several editorial boards, and serves as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, HIV eradication and more recently, COVID-19. Dr. Kuritzkes is rated as an Elite provider by MediFind in the treatment of HIV/AIDS. His top areas of expertise are HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome.
Dr. Thomas Quinn is professor of medicine and pathology in the Johns Hopkins School of Medicine and professor of international health, epidemiology, and molecular microbiology and immunology in The Johns Hopkins School of Public Health, and professor of nursing in the Johns Hopkins School of Nursing. In 2006 he was appointed founding Director of the Johns Hopkins University Center for Global Health. He serves as advisor/consultant on HIV and STDs to the World Health Organization, Office of the Global AIDS Coordinator (PEPFAR), UNAIDS, and the FDA. He serves as Associate Director for International Research at the National Institute of Allergy and Infectious Diseases. He is a member of the Institute of Medicine of the National Academy of Sciences, and is a fellow of the American Association for the Advancement of Science. He is a fellow of the Infectious Diseases Society of America and a member of the American Association of Physicians. He is an author of over 900 publications on HIV, STDs, and infectious diseases, and serves on multiple editorial boards. Among his professional activities, Dr. Quinn is an alternate member of the Technical Panel of the Global Fund to Fight AIDS, Malaria, and Tuberculosis and has been on Advisor/Consultant on HIV and STDs to the World Health Organization, UNAIDS, and the U.S. Food and Drug Administration. In October 2004 he received membership in the Institute of Medicine. Dr. Quinn is rated as an Elite provider by MediFind in the treatment of HIV/AIDS. His top areas of expertise are HIV/AIDS, Genital Herpes, Chlamydia, and Human Papillomavirus Infection.
Brigham And Womens Physicians Organization Inc
Dr. Paul E. Sax is Clinical Director of the Division of Infectious Diseases at Brigham and Women's Hospital (BWH), where he holds the Bruce and Robert Beal Distinguished Chair, and Professor of Medicine at Harvard Medical School. Dr. Sax received his MD from Harvard Medical School, did his residency in Internal Medicine at BWH, then fellowship in Infectious Diseases at Massachusetts General Hospital.He is Editor-in-Chief of Open Forum Infectious Diseases, is Section Editor of HIV/AIDS in UpToDate, on the Editorial Board of NEJM Journal Watch Infectious Diseases (where he writes the HIV and ID Observations blog), and on the editorial advisory board of Medscape HIV/AIDS. Dr. Sax is the Associate Program Director for the Mass General Brigham fellowship in Infectious Diseases, is on the core faculty of the International Antiviral Society – USA, and teaches regularly on HIV and infectious diseases locally, nationally, and internationally. In addition to his clinical practice and teaching, Dr. Sax’s ongoing areas of research include clinical trials of antiretroviral therapies, cost-effectiveness of management strategies for HIV, and toxicity of antiretroviral therapy. He is presently the principal investigator at the BWH AIDS Clinical Trials Unit, and is a member of the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) Research Group. Dr. Sax is rated as an Elite provider by MediFind in the treatment of HIV/AIDS. His top areas of expertise are HIV/AIDS, Nontuberculous Mycobacterial Lung Disease, Myelitis, and AIDS Dementia Complex.
Joining a support group where members share common experiences and problems can often help lower the emotional stress of having a long-term illness.
With treatment, most people with HIV/AIDS can live a healthy and normal life.
Current treatments do not cure the infection. The medicines only work as long as they are taken every day or as prescribed. If the medicines are stopped, the viral load will go up and the CD4 count will drop. If the medicines are not taken regularly, the virus can become resistant to one or more of the medicines, and the treatment will stop working.
People who are on treatment need to see their health care providers regularly. This is to make sure the medicines are working and to check for side effects of the medicines.
Contact your provider for an appointment if you have any risk factors for HIV infection. Also contact your provider if you develop symptoms of AIDS. By law, the results of HIV testing must be kept confidential (private). Your provider will review your test results with you.
Preventing HIV/AIDS:
- Get tested. People who don't know they have HIV infection and who look and feel healthy are the most likely to transmit it to others.
- Do not use illegal drugs and do not share needles or syringes. Many communities have needle exchange programs where you can get rid of used syringes and get new, sterile ones. Staff at these programs can also refer you for substance use disorder treatment.
- Avoid contact with another person's blood. If possible, wear protective clothing, a mask, and goggles when caring for people who are injured.
- If you test positive for HIV, you can pass the virus to others. You should not donate blood, plasma, body organs, or sperm.
- HIV-positive women who might become pregnant should talk to their provider about the risk to their unborn child. They should also discuss methods to prevent their baby from becoming infected, such as taking antiretroviral medicines during pregnancy.
- Breastfeeding should be avoided to prevent passing HIV to infants through breast milk.
Safer sex practices, such as using latex condoms, are effective in preventing the spread of HIV. But there is still a risk of getting the infection, even with the use of condoms (for example, condoms can tear).
In people who aren't infected with the virus, but are at high risk of getting it, certain medicines can help prevent infection.
- Truvada (emtricitabine and tenofovir disoproxil fumarate) - taken as a pill
- Descovy (emtricitabine and tenofovir alafenamide) - taken as a pill
- Apretude (cabotegravir) - given as a shot every other month to help prevent infection
This treatment is known as pre-exposure prophylaxis, or PrEP. Talk to your provider if you think PrEP might be right for you.
People who are HIV-positive, taking antiretroviral medicines, and have no detectible virus in their blood do not transmit the virus.
The US blood supply is among the safest in the world. Nearly all people infected with HIV through blood transfusions received those transfusions before 1985, the year HIV testing began for all donated blood.
If you believe you have been exposed to HIV, seek medical attention right away. Do not delay. Starting antiviral medicines right after the exposure (up to 3 days after) can reduce the chance that you will be infected. This is called post-exposure prophylaxis (PEP). It has been used to prevent transmission in health care workers injured by needlesticks.
Summary: Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
Summary: Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
Published Date: May 12, 2025
Published By: Jatin M. Vyas, MD, PhD, Roy and Diana Vagelos Professor in Medicine, Columbia University Vagelos College of Physicians and Surgeons, Division of Infectious Diseases, Department of Medicine, New York, NY. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Centers for Disease Control and Prevention website. HIV. About HIV. www.cdc.gov/hiv/about/index.html. Updated January 14, 2025. Accessed May 22, 2025.
Centers for Disease Control and Prevention website. HIV. Preventing HIV with PrEP. www.cdc.gov/hiv/prevention/prep.html/. Reviewed January 18, 2024. Accessed May 22, 2025.
Clinicalinfo.HIV.gov website. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human. Reviewed January 8, 2025. Accessed July 17, 2025.
Kleinpeter AP, Freed EO. Human immunodeficiency viruses. In: Blaser MJ, Cohen JI, Holland SM, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 10th ed. Philadelphia, PA: Elsevier; 2026:chap 120.
Merrick ST, Glesby MJ. Systemic manifestations of HIV/AIDS. Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 359.
Peters C, Pham P, Maldarelli F. Diagnosis of human immunodeficiency virus infection. In: Blaser MJ, Cohen JI, Holland SM, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 10th ed. Philadelphia, PA: Elsevier; 2026:chap 123.
Tsibris AMN, Hirsch MS. Antiretroviral therapy for human immunodeficiency virus infection. In: Blaser MJ, Cohen JI, Holland SM, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 10th ed. Philadelphia, PA: Elsevier; 2026:chap 130.
US Department of Health and Human Services, Clinical Info HIV.gov website. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new. Updated September 25, 2025. Accessed October 21, 2025.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, et al. Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;321(23):2326-2336. PMID: 31184701 pubmed.ncbi.nlm.nih.gov/31184701/.